Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2009.
|
| Edición: | 1st ed. 2009. |
| Colección: | Cancer Drug Discovery and Development,
|
| Materias: |
Tabla de Contenidos:
- Genomic Experimental Approaches in Oncology
- Toward the Realization of the Promise of Microarrays in Oncology
- Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response
- Proteomic Analysis in Cancer Patients
- MicroRNAs and Discovery of New Targets
- Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panel
- Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers
- Pharmacogenomics of Toxicity and Response of Chemotherapy
- Concordance Between Tumor and Germline DNA
- Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer
- BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients
- Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients
- Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene
- Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies
- DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer
- Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killer
- Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment
- Microarray Profiling in Breast Cancer Patients
- Role of the Folate-Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response
- Pharmacogenomics in Clinical Drug Development in Oncology
- Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective
- Identification of Pharmacogenomic Biomarker Classifiers in Cancer Drug Development
- Toxicogenomics Application to Oncology Drug Development
- Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches.